An interventional study of Roux-en-Y gastric bypass and Sleeve gastrectomy in Diabetes and Obesity, sponsored by Ethicon Endo-Surgery. Completed at 6 sites in China. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Ethicon Endo-Surgery (part of Johnson & Johnson) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Diabetes Mellitus by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus · Johnson & Johnson.
Among the 28 studies in Diabetes Mellitus by Johnson & Johnson, this one is the 14th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2014, is one of 10 with no phase, and was the 17th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →None of the 28 studies in Diabetes Mellitus by Johnson & Johnson is open now. The open studies under Diabetes Mellitus, anywhere →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 20 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 101 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 129 across the 24 interventional studies, 1,603 across the 3 observational. Of the 26 that completed or were terminated, 7 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Ethicon Endo-Surgery, one of the names counted as Johnson & Johnson. Under that name alone:
Ethicon Endo-Surgery is the lead sponsor of 47 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 28 studies in Diabetes Mellitus by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary goal of this study is to assess impact of metabolic surgery on glycemic control in diabetic patients.
The primary objective of this study is to assess the impact of metabolic surgery (Roux-en-Y gastric bypass [RYGB] or sleeve gastrectomy [SG]) on composite measure of glycemic control at 2 years post surgery in a Type 2 Diabetes Mellitus (T2DM) cohort of subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who receive a Roux-en-Y gastric bypass
Procedure: Roux-en-Y gastric bypass
Subjects who receive a sleeve gastrectomy
Procedure: Sleeve gastrectomy
Composite Measure of Glycemic Control - Complete Remission
Normal measures of glucose metabolism (glycosylated hemoglobin A1c \[HbA1c\] \< 6% \[7.0 mmol/L\] and fasting plasma glucose \[FPG\] \< 100 mg/dL \[5.6 mmol/L\]) for 1 year in the absence of antidiabetic medications;
Time frame: 2 years
Composite Measure of Glycemic Control - Partial remission
Hyperglycemia (HbA1c 6% - 6.4% \[7.0 - 7.6 mmol/L\] and FPG 100 - 125 mg/dL \[5.6 mmol/L - 6.9 mmol/L\]) for 1 year in the absence of anti-diabetic medications;
Time frame: 2 years
Composite Measure of Glycemic Control - Improvement
Significant reduction in HbA1c (by \> 1%) or FPG (\> 25 mg/dL \[1.4 mmol/L\]) OR reduction in HbA1c and FPG accompanied by a decrease in antidiabetic medication requirement (by discontinuing insulin or 1 oral agent, or ½ reduction in dose) for at least 1-year duration;
Time frame: 2 years
Composite Measure of Glycemic Control - Unchanged
The absence of remission or improvement as described earlier;
Time frame: 2 years
Composite Measure of Glycemic Control - Recurrence
FPG or HbA1c in the diabetic range (≥ 126 mg/dL \[7.0 mmol/L\] and ≥ 6.5% \[7.8 mmol/L\], respectively) OR need for antidiabetic medication after initial complete or partial remission.
Time frame: 2 years
Composite Measure of Glycemic Control
The composite measure of glycemic control will be defined as previously described in the primary outcome measure.
Time frame: 5 years
Evaluation of diabetic nephropathy
Evaluate long-term diabetic nephropathy
Time frame: 5 years
Evaluation of diabetic retinopathy
Evaluate long-term diabetic retinopathy.
Time frame: 5 years
Assess changes in HbA1c
Assess changes in HbA1c after the procedure is performed.
Time frame: 5 years
Assess changes in Weight (kg)
Assess changes in weight after the procedure is performed.
Time frame: 5 years
Assess changes in BMI
Assess changes in BMI after the procedure is performed.
Time frame: 5 years
Assess changes in high-density lipoprotein (HDL) (mg/dL and mmol/L)
Assess changes in high-density lipoprotein (HDL) (mg/dL and mmol/L) after the procedure is performed
Time frame: 5 years
Assess changes in low-density lipoprotein (LDL) (mg/dL and mmol/L
Assess changes in low-density lipoprotein (LDL) (mg/dL and mmol/L) after the procedure is performed.
Time frame: 5 years
Assess changes in triglycerides (TG) (mg/dL and mmol/L)
Assess changes in triglycerides (TG) (mg/dL and mmol/L) after the procedure is performed.
Time frame: 5 years
Assess changes in cholesterol (mg/dL and mmol/L)
Assess changes in cholesterol (mg/dL and mmol/L) after the procedure is performed.
Time frame: 5 years
Assess changes in FPG (mg/dL and mmol/L)
Assess changes in FPG (mg/dL and mmol/L) after the procedure is performed
Time frame: 5 years
Assess changes in insulin (µU/mL and pmol/L)
Assess changes in insulin (µU/mL and pmol/L) after the procedure is performed
Time frame: 5 years
Assess changes in serum albumin level (g/L)
Assess changes in serum albumin level (g/L) after the procedure is performed
Time frame: 5 years
Assess changes in alanine aminotransferase (ALT) level (Unit [U]/L)
Assess changes in alanine aminotransferase (ALT) level (Unit \[U\]/L) after the procedure is performed
Time frame: 5 years
Assess changes in aspartate aminotransferase (AST) level (U/L)
Assess changes in aspartate aminotransferase (AST) level (U/L) after the procedure is performed
Time frame: 5 years
Assess changes in gamma-glutamyl transferase (GGT) level (U/L)
Assess changes in gamma-glutamyl transferase (GGT) level (U/L) after the procedure is performed
Time frame: 5 years
Assess changes in creatinine levels (mg/dL and mmol/L)
Assess changes in creatinine levels (mg/dL and mmol/L) after the procedure is performed
Time frame: 5 years
Assess changes in blood urea nitrogen (BUN) levels (mg/dL and mmol/L)
Assess changes in blood urea nitrogen (BUN) levels (mg/dL and mmol/L) after the procedure is performed
Time frame: 5 years
Assess changes in anti-hypertensive medication
Assess changes in anti-hypertensive medication after the procedure is performed
Time frame: 5 years
Asses the changes in lipid lowering medication
Asses the changes in lipid lowering medication after the procedure is performed
Time frame: 5 years
Assess the changes in hyperglycemia medication
Assess the changes in hyperglycemia medication after the procedure is performed
Time frame: 5 years
Assess the changes in SF-36 Health Survey
Assess the changes in SF-36 Health Survey after the procedure is performed
Time frame: 5 years
Ran from Jul 2014 to primary completion in Jun 2018, 46 months.
Of 160 industry-sponsored interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's 46 months is above that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.